ClinicalTrials.gg
TerminatedNCT03684642AMPLITUDE-DUpdated Nov 1, 2021Results posted

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

A Phase 3 interventional study of Efpeglenatide and Dulaglutide in Type 2 Diabetes Mellitus, sponsored by Sanofi. Terminated at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to cancel TRIAL, not related to safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
908
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
16th of 178
908 · median 334
Started
2018
with 11 others
Phase 3
80 of 186
none open now
Registered
164th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 16th largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2018, is one of 80 in phase 3, and was the 164th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin.

Secondary Objectives:

  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control.
  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight.
  • To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide.
Read the detailed description

Study duration per participant was approximately 65 weeks including an up to 3-week Screening Period, a 56-week Treatment Period and a 6-week safety Follow-up Period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than or equal to (>=) 18 years of age at the time of signing the .
  • Participants with T2DM.
  • Diabetes diagnosed at least 1 year before screening.
  • Participants on stable dose of at least 1500 milligram per day (mg/day) of metformin, or tolerated maximum dose, or as per country regulation if less, for at least 3 months prior to screening.
  • between 7.0 percent (%) and 10.0% (inclusive) measured by the central laboratory at screening.

Exclusion criteria

Exclusion criteria:

  • Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.
  • history of gastrointestinal (GI) disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease requiring medical treatment within 6 months prior to screening or history of surgery affecting gastric emptying.
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy had been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
  • Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g., multiple endocrine neoplasia syndromes).
  • Body weight change of greater than or equal to (>=) 5 kilogram within the last 3 months prior to screening.
  • Systolic blood pressure greater than (>)180 millimeter of mercury (mmHg) and/or diastolic blood pressure >100 mmHg at randomization.
  • Severe renal disease as defined by estimated (eGFR), by Modification of Diet in Renal Disease (MDRD)] of less than (\<)30 mL/min/1.73 m\^2.
  • Laboratory findings at the screening visit:
  • (ALT) or aspartate aminotransferase (AST) >3 * (ULN) or total >1.5 * ULN (except in case of documented Gilbert's syndrome);
  • Amylase and/or lipase: >3 * ULN;
  • Calcitonin >=5.9 picomoles per liter (pmol/L) (20 picograms per milliliter).
  • Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to screening, or planned during study period.
  • Pregnant (confirmed by serum pregnancy test at screening) or breast-feeding women.
  • Women of (WOCBP) not willing to use highly effective method(s) of or who are unwilling to be tested for pregnancy during the study period and for at least 5 weeks after the last dose of study intervention.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
908 participants (actual)

Study arms

  • Experimental
    Efpeglenatide 4 mg

    Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.

    Drug: Efpeglenatide · Drug: Background therapy Metformin

  • Experimental
    Efpeglenatide 6 mg

    Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.

    Drug: Efpeglenatide · Drug: Background therapy Metformin

  • Active comparator
    Dulaglutide 1.5 mg

    Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.

    Drug: Dulaglutide · Drug: Background therapy Metformin

Interventions

  • Pharmaceutical form: solution for injection; Route of administration: SC

    Also known as: SAR439977

  • Pharmaceutical form: solution for injection; Route of administration: SC

    Also known as: Trulicity™

  • DrugBackground therapy Metformin

    Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 56 in HbA1c

    Adjusted Least square (LS) means and Standard errors (SE) were obtained from analysis of covariance (ANCOVA) model to account for missing data. Missing values were imputed by baseline observation carried forward (BOCF)-like multiple imputation method.

    Time frame: Baseline to Week 56

Secondary outcomes

  1. Change From Baseline to Week 56 in Body Weight

    Adjusted LS means and SE were obtained from ANCOVA model to account for missing data. Missing values were imputed by BOCF-like multiple imputation method.

    Time frame: Baseline to Week 56

  2. Number of Participants With HbA1c < 7.0 %

    Participants who had no available assessment for HbA1c at Week 56 were considered as non-responders.

    Time frame: Week 56

  3. Change From Baseline to Week 56 in Fasting Plasma Glucose (FPG)

    Adjusted LS means and SE were obtained from ANCOVA model to account for missing data. Missing values were imputed by BOCF-like multiple imputation method.

    Time frame: Baseline to Week 56

  4. Number of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], Severe Hypoglycemia)

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 milligrams per deciliter (mg/dL) (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

    Time frame: Baseline up to Week 56

  5. Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

    Time frame: Baseline up to Week 56

07

Results

Posted Nov 1, 2021
Limitations and caveats
The study was terminated early by the Sponsor on 09 September 2020. Due to early termination of the study, model-based efficacy analyses were performed in the mITT population instead of the ITT population originally planned and data was carefully considered given that the study was terminated early.

Participant flow

The study was conducted at 45 active sites in 4 countries. A total of 1608 participants were screened between 26 September 2018 and 17 December 2019, out of which 700 were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestoneEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Started303302303
Treated303302302
Safety population313292302
Completed200169197
Not completed103133106
Withdrew: Adverse event61511
Withdrew: Withdrawal by subject355323
Withdrew: Lack of efficacy001
Withdrew: Poor compliance to protocol041
Withdrew: Other than specified626067
Withdrew: Randomized and not treated001
Withdrew: Missing completion status but alive at last contact012

Outcome measures

PrimaryChange From Baseline to Week 56 in HbA1c

Adjusted Least square (LS) means and Standard errors (SE) were obtained from analysis of covariance (ANCOVA) model to account for missing data. Missing values were imputed by baseline observation carried forward (BOCF)-like multiple imputation method.

Time frame:
Baseline to Week 56
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline to Week 56 in HbA1c
percentage of HbA1cEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Change From Baseline to Week 56 in HbA1c-1.12 ± 0.06-1.17 ± 0.06-1.09 ± 0.06
Statistical analysis
  • Efpeglenatide 4 mg vs Dulaglutide 1.5 mg · Least square (ls) mean difference: -0.03 · 95% CI -0.20 to 0.14
  • Efpeglenatide 6 mg vs Dulaglutide 1.5 mg · Ls mean difference: -0.08 · 95% CI -0.25 to 0.09
  • Efpeglenatide 4 mg vs Dulaglutide 1.5 mg · ANCOVA · p = 0.7064 (Threshold for significance at the level of 0.05.)
  • Efpeglenatide 6 mg vs Dulaglutide 1.5 mg · ANCOVA · p = 0.3427 (Threshold for significance at the level of 0.05.)
SecondaryChange From Baseline to Week 56 in Body Weight

Adjusted LS means and SE were obtained from ANCOVA model to account for missing data. Missing values were imputed by BOCF-like multiple imputation method.

Time frame:
Baseline to Week 56
Reported as:
Least squares mean · kilogram
Change From Baseline to Week 56 in Body Weight
kilogramEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Change From Baseline to Week 56 in Body Weight-2.87 ± 0.64-3.04 ± 0.67-2.81 ± 0.66
SecondaryNumber of Participants With HbA1c < 7.0 %

Participants who had no available assessment for HbA1c at Week 56 were considered as non-responders.

Time frame:
Week 56
Reported as:
Count of participants · Participants
Number of Participants With HbA1c < 7.0 %
ParticipantsEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Number of Participants With HbA1c < 7.0 %155157150
SecondaryChange From Baseline to Week 56 in Fasting Plasma Glucose (FPG)

Adjusted LS means and SE were obtained from ANCOVA model to account for missing data. Missing values were imputed by BOCF-like multiple imputation method.

Time frame:
Baseline to Week 56
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to Week 56 in Fasting Plasma Glucose (FPG)
millimoles per liter (mmol/L)Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Change From Baseline to Week 56 in Fasting Plasma Glucose (FPG)-1.81 ± 0.15-1.57 ± 0.15-1.71 ± 0.15
SecondaryNumber of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], Severe Hypoglycemia)

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 milligrams per deciliter (mg/dL) (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Time frame:
Baseline up to Week 56
Reported as:
Count of participants · Participants
Number of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], Severe Hypoglycemia)
ParticipantsEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Documented symptomatic hypoglycemia (<54 mg/dL)310
Severe hypoglycemia000
SecondaryNumber of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Time frame:
Baseline up to Week 56
Reported as:
Number · events per participant-year
Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year
events per participant-yearEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Documented symptomatic hypoglycemia (<54 mg/dL)0.010.010
Severe hypoglycemia000

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent up to end of study. Time frame for reporting of treatment emergent adverse events (TEAEs) was from first dose up to 30 days after the last injection of the Investigational Medicinal Product (IMP) (Week 60).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efpeglenatide 4 mg0/313 (0%)20/313 (6.4%)202/313 (64.5%)
Efpeglenatide 6 mg0/292 (0%)23/292 (7.9%)180/292 (61.6%)
Dulaglutide 1.5 mg1/302 (0.3%)20/302 (6.6%)178/302 (58.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
Acute Myocardial InfarctionCardiac disorders1/3132/2920/302
Atrioventricular Block CompleteCardiac disorders0/3132/2920/302
CholelithiasisHepatobiliary disorders1/3132/2920/302
Atrial FibrillationCardiac disorders1/3131/2922/302
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/3130/2922/302
Coronary Artery DiseaseCardiac disorders2/3130/2920/302
DiverticulitisInfections and infestations1/3131/2920/302
GastroenteritisInfections and infestations1/3131/2920/302
SepsisInfections and infestations0/3131/2921/302
Benign Salivary Gland NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3131/2920/302
Most frequent other events
Showing 10 of 11
Most frequent other events
EventEfpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mg
DiarrhoeaGastrointestinal disorders93/31383/29290/302
NauseaGastrointestinal disorders85/31383/29278/302
Decreased AppetiteMetabolism and nutrition disorders38/31350/29236/302
VomitingGastrointestinal disorders41/31345/29237/302
ConstipationGastrointestinal disorders32/31334/29219/302
Abdominal PainGastrointestinal disorders24/31330/29216/302
Lipase IncreasedInvestigations27/31319/29224/302
DyspepsiaGastrointestinal disorders26/31317/29215/302
Abdominal Pain UpperGastrointestinal disorders22/31316/29218/302
Upper Respiratory Tract InfectionInfections and infestations21/31318/29220/302

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) population, which included all randomized participants, analyzed according to the treatment group allocated by randomization.

Age, Continuous
Age, Continuous(years)Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mgTotal
Mean60.3 ± 9.660.0 ± 10.159.4 ± 10.159.9 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mgTotal
Female142157153452
Male161145150456
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mgTotal
White271263275809
Black or African American24301872
Asian53614
Other3429
Not reported0224
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mgTotal
Mean33.4 ± 6.133.4 ± 6.233.4 ± 6.433.4 ± 6.2
Baseline Glycated Hemoglobin (HbA1c %)
Baseline Glycated Hemoglobin (HbA1c %)(percentage of HbA1c)Efpeglenatide 4 mgEfpeglenatide 6 mgDulaglutide 1.5 mgTotal
Mean8.12 ± 0.828.07 ± 0.788.11 ± 0.818.10 ± 0.81
08

Study locations

45 sites
  • Investigational Site Number 8400038
    Birmingham, Alabama 35211, United States
  • Investigational Site Number 8400035
    Chandler, Arizona 85224, United States
  • Investigational Site Number 8400005
    Glendale, Arizona 85306, United States
  • Investigational Site Number 8400054
    Peoria, Arizona 85381, United States
  • Investigational Site Number 8400057
    Huntington Park, California 90255, United States
  • Investigational Site Number 8400009
    Los Angeles, California 90057, United States
  • Investigational Site Number 8400007
    San Diego, California 92120, United States
  • Investigational Site Number 8400045
    Spring Valley, California 91978, United States
  • Investigational Site Number 8400040
    Tustin, California 92780, United States
  • Investigational Site Number 8400026
    Van Nuys, California 91405, United States
  • Investigational Site Number 8400050
    Waterbury, Connecticut 06708, United States
  • Investigational Site Number 8400055
    Orlando, Florida 32825, United States
  • Investigational Site Number 8400041
    Pembroke Pines, Florida 33026, United States
  • Investigational Site Number 8400025
    Lawrenceville, Georgia 30044, United States
  • Investigational Site Number 8400060
    Meridian, Idaho 83642, United States
  • Investigational Site Number 8400059
    Skokie, Illinois 60077, United States
  • Investigational Site Number 8400044
    Lexington, Kentucky 40503, United States
  • Investigational Site Number 8400061
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 8400001
    Bridgeton, New Jersey 08302, United States
  • Investigational Site Number 8400039
    New Windsor, New York 12553, United States
  • Investigational Site Number 8400028
    Burlington, North Carolina 27215, United States
  • Investigational Site Number 8400036
    Morehead City, North Carolina 28557, United States
  • Investigational Site Number 8400013
    Maumee, Ohio 43537, United States
  • Investigational Site Number 8400014
    Goose Creek, South Carolina 29445, United States
  • Investigational Site Number 8400030
    Dallas, Texas 75230, United States
  • Investigational Site Number 8400020
    San Antonio, Texas 78218, United States
  • Investigational Site Number 8400043
    San Antonio, Texas 78229, United States
  • Investigational Site Number 8400053
    San Antonio, Texas 78258, United States
  • Investigational Site Number 8400037
    Layton, Utah 84041, United States
  • Investigational Site Number 8400049
    Manassas, Virginia 20110, United States
  • Investigational Site Number 3480004
    Budapest, 1036, Hungary
  • Investigational Site Number 3480003
    Debrecen, 4025, Hungary
  • Investigational Site Number 3480001
    Gyula, 5700, Hungary
  • Investigational Site Number 3480005
    Hatvan, 3000, Hungary
  • Investigational Site Number 3480002
    Nyíregyháza, 4400, Hungary
  • Investigational Site Number 6160008
    Gdansk, 80-382, Poland
  • Investigational Site Number 6160004
    Gdynia, 81-537, Poland
  • Investigational Site Number 6160010
    Katowice, 40-040, Poland
  • Investigational Site Number 6160009
    Poznan, 60-702, Poland
  • Investigational Site Number 6160003
    Warszawa, 01-192, Poland
  • Investigational Site Number 6160001
    Wroclaw, 50-381, Poland
  • Investigational Site Number 8040003
    Kyiv, 02002, Ukraine
  • Investigational Site Number 8040001
    Kyiv, 03037, Ukraine
  • Investigational Site Number 8040002
    Kyiv, 03049, Ukraine
  • Investigational Site Number 8040004
    Vinnytsia, 21050, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No plan to share individual participant data (IPD) by SANOFI: Product rights transferred to Hanmi Pharmaceutical.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Oct 2020, 24 months.

Results were first posted in Nov 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Sep 26, 2018
StartActual
Sep 26, 2018
Primary completionActual
Oct 13, 2020
CompletionActual
Nov 17, 2020
Results first posted
Nov 1, 2021
Last update
Nov 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03684642
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 26, 2018
Start date
Sep 26, 2018
Primary completion
Oct 13, 2020
Completion
Nov 17, 2020
Results posted
Nov 1, 2021
Last update
Nov 1, 2021

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion